T. Rowe Price Associates’s aTyr Pharma ATYR Stock Holding History

T. Rowe Price Associates’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$36K	Hold	46,126	–	–	﹤0.01%	3087
2025 Q4	$36K	Hold	46,126	–	–	﹤0.01%	3063
2025 Q3	$34K	Buy	46,126 +2,601	+6%	+$11.8K	﹤0.01%	3025
2025 Q2	$221K	Buy	+43,525	New	+$171K	﹤0.01%	2667
2021 Q4	–	Sell	-12,024	Closed	-$109K	–	3046
2021 Q3	$109K	Buy	+12,024	New	+$71.9K	﹤0.01%	2828
2016 Q2	–	Sell	-37,175	Closed	-$2.05M	–	2536
2016 Q1	$2.05M	Sell	37,175 -46,326	-55%	-$3.52M	﹤0.01%	1514
2015 Q4	$11.5M	Sell	83,501 -1,078	-1%	-$153K	﹤0.01%	1249
2015 Q3	$11.8M	Sell	84,579 -424	-0.5%	-$96.6K	﹤0.01%	1266
2015 Q2	$21.4M	Buy	+85,003	New	+$26.4M	﹤0.01%	1118

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates's ATYR Position: Q1 2026 in Review

T. Rowe Price Associates held its aTyr Pharma (ATYR) position steady in Q1 2026 at 46,126 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #3087.

T. Rowe Price Associates first reported a position in ATYR in Q2 2015 and has held it in 9 quarters since. The position peaked at $21.4M in Q2 2015. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

T. Rowe Price Associates held 46,126 shares of aTyr Pharma worth $36K as of Q1 2026.
T. Rowe Price Associates left its aTyr Pharma share count unchanged in Q1 2026.
aTyr Pharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3087 holding.
T. Rowe Price Associates first reported a position in aTyr Pharma in Q2 2015 and has held it in 9 quarters since.
T. Rowe Price Associates's aTyr Pharma position peaked at $21.4M in Q2 2015.
111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.